GLP-1 Peptide Atlas, by Delfa

CompletedPhase 1

STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY

A 2-PART, PHASE 1, OPEN LABEL STUDY WITH A 4-PERIOD, 4-SEQUENCE, CROSSOVER DESIGN IN COHORT 1 AND A 2-PERIOD, 2-SEQUENCE CROSSOVER DESIGN IN COHORT 2 TO COMPARE THE SINGLE DOSE PHARMACOKINETICS OF FIVE DIFFERENT FORMULATIONS OF PF-06882961 ADMINISTERED ORALLY TO OTHERWISE HEALTHY ADULT PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY

Lead sponsor

Pfizer

Asset

Danuglipron

Oral · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Obesity / overweight

Key I/E criteria

•BMI 25-40•Healthy volunteers

Primary endpoints

•Area Under the Curve•Cmax for Formulations A and B cohort 1•Cmax for Formulations A and E cohort 2

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04616339

Org study IDC3421010

Secondary ID2020-001016-24

Timeline

Milestones

Study first posted2020-11-04actual

Study start2020-11-04actual

Primary completion2021-07-19actual

Study completion2021-07-19actual

Last update posted2022-04-04actual

Assets

Investigational agents

Danuglipron

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age55 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Male and female participants must be 18 to 55 years of age, inclusive, at the time of signing the ICD.

•Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vitals and ECGs. Participants with obesity that are otherwise healthy may be enrolled in this study.

•Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.

•A total body weight >50 kg (110 lb) and BMI of 25.0 to 40.0 kg/m2 at the screening visit.

•Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and protocol.

Exclusion criteria

•Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).

•Any condition possibly affecting drug absorption (eg, gastrectomy).

•History of HIV infection, hepatitis B, or hepatitis C; positive testing for HBsAg, HBsAb, HBcAb, HCVAb or HIV. Hepatitis B vaccination is allowed.

•Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), or participants with suspected MTC per the investigator's judgement.

•Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

•Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 halflives (whichever is longer) prior to the first dose of study intervention.

•Use of hormone replacement therapy or oral/injectable contraceptives.

•Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer).

•Participants with known prior participation (ie, randomized and received at least 1 dose of investigational product) in a study involving PF 06882961.

•A positive urine drug test.

•Using a properly sized and calibrated BP cuff, screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic) following at least 5 minutes of supine rest. If BP is ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic) the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.

•Baseline 12 lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, baseline QTcF interval >450 msec, complete LBBB, signs of an acute or indeterminate age myocardial infarction, ST T interval changes suggestive of myocardial ischemia, second or third degree AV block, or serious bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is >450 msec, this interval should be rate corrected using the Fridericia method and the resulting QTcF should be used for decision making and reporting. If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTcF or QRS values should be used to determine the participant's eligibility. Computer interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding participants.

•Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:

–Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≥1.25 × upper limit of normal (ULN);

–Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ≤ ULN.

–HbA1c ≥6.5%;

–Fasting blood glucose ≥126 mg/dL (7 mmol/L);

–Calcitonin > ULN;

–eGFR <60 mL/min/1.73 m2 as calculated by the CKD-EPI equation.

Endpoints (13)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

13 endpoints

Primary/protocol endpoint

Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for Formulations A and B cohort 1

Time frame:Day 1 hour (hr) 0, 1, 2, 3, 4, 6, 8, 10, 12, 16, Day 2 hr 24 and 36, Day 3 hr 48 and end of study (Day 28)

AUC₀–∞

concentration, descriptive

Primary/protocol endpoint

Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Formulations A and B cohort 1

Time frame:Day 1 hr 0, 1, 2, 3, 4, 6, 8, 10, 12, 16, Day 2 hr 24 and 36 and Day 3 hr 48

concentration, descriptive

Primary/protocol endpoint

Maximum Observed Plasma Concentration (Cmax) for Formulations A and B cohort 1

Time frame:Day 1 hr 0, 1, 2, 3, 4, 6, 8, 10, 12, 16, Day 2 hr 24 and 36 and Day 3 hr 48

Cmax

concentration, descriptive

Primary/protocol endpoint

Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for Formulations A and E cohort 2

Time frame:Day 1 hour (hr) 0, 1, 2, 3, 4, 6, 8, 10, 12, 16, Day 2 hr 24 and 36, Day 3 hr 48 and end of study (Day 28)

AUC₀–∞

concentration, descriptive

Primary/protocol endpoint/low confidence

Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Formulations A and E cohort 2

Time frame:Day 1 hr 0, 1, 2, 3, 4, 6, 8, 10, 12, 16, Day 2 hr 24 and 36 and Day 3 hr 48

concentration, descriptive

Primary/protocol endpoint

Maximum Observed Plasma Concentration (Cmax) for Formulations A and E cohort 2

Time frame:Day 1 hr 0, 1, 2, 3, 4, 6, 8, 10, 12, 16, Day 2 hr 24 and 36 and Day 3 hr 48

Cmax

concentration, descriptive

Secondary/protocol endpoint

Number of Subjects Reporting Treatment-emergent adverse events (AEs)

Time frame:Baseline through End of Study(Day 28)

Treatment-emergent AEs (any)

event count, event

Secondary/protocol endpoint

Number of Participants With Clinical Laboratory Abnormalities

Time frame:Baseline, Day 1 and Day 3

descriptive

Secondary/protocol endpoint

Number of Participants With Clinically Significant Change From Baseline in Vital Signs

Time frame:Baseline, Day 1 and Day 3

descriptive

Secondary/protocol endpoint

Number of Participants With Abnormal Electrocardiogram (ECG)

Time frame:Baseline, Day 1 and Day 3

threshold achievement, event

Secondary/protocol endpoint

Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) for Formulations C and D

Time frame:Day 1 hr 0, 1, 2, 3, 4, 6, 8, 10, 12, 16, Day 2 hr 24 and 36 and Day 3 hr 48

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Formulations C and D

Time frame:Day 1 hr 0, 1, 2, 3, 4, 6, 8, 10, 12, 16, Day 2 hr 24 and 36 and Day 3 hr 48

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

Maximum Observed Plasma Concentration (Cmax) for Formulations C and D

Time frame:Day 1 hr 0, 1, 2, 3, 4, 6, 8, 10, 12, 16, Day 2 hr 24 and 36 and Day 3 hr 48

Cmax

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.